Skip to content

Performance of a Multifocal Contact Lens - Presbyopia Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02450747
Enrollment
44
Registered
2015-05-21
Start date
2015-04-30
Completion date
2015-09-30
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia

Keywords

Visual Acuity

Brief summary

This is a four week study to evaluate the performance of a multifocal contact lens in habitual wearers of silicone hydrogel multifocal contact lenses.

Interventions

Subjects will wear the test lens for four weeks.

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy adult males or females age 40 to 70 and has full legal capacity to volunteer. 2. The subject is a current spherical silicone hydrogel multifocal (SiHy) contact lens wearer (defined as a minimum of 2 days per week for at least 6 hours of Daily Wear contact lenses, for a minimum of one month prior to the study) and willing to wear the study lenses on a daily basis (defined as a minimum of 6 hours of wear per day) for the duration of the study. 3. The subject must own a pair of wearable spectacles to wear when they cannot wear the study lenses. 4. The subject's optimal vertexed spherical equivalent distance correction must be between +3.50 and -5.50 Diopters (D) (inclusive) in both eyes. 5. Subjective refraction cylinder power must be less than or equal to 0.75 D in both eyes. 6. Requires a reading addition of +0.75 D to +2.50 D in each eye. 7. The subject must have distance and near visual acuity best correctable to logMAR 0.1 (20/25) or better at both distance and near with subjective refraction for each eye. 8. The subject must read and sign the Informed Consent form. 9. The subject must appear able and willing to adhere the instructions set forth in this clinical protocol.

Exclusion criteria

1. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 2. Participant in unrelated research clinical trial within 30 days prior to enrollment; 3. Known to have any infectious disease (e.g.hepatitis, tuberculosis) or a contagious immunosuppressive disease. 4. Women who are pregnant or lactating or planning a pregnancy at the time of enrollment; 5. Ocular or systemic allergies or disease which might interfere with contact lens wear; 6. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes. 7. Systemic disease or use of medication which might interfere with contact lens wear; 8. Any corneal distortion; 9. Has any known active\* ocular disease and/or infection; 10. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; and only uses rewetting drops on an occasional basis( greater than 2 times per week). 11. Is a habitual monovision contact lens wearer wearing contact lenses on extended wear basis or for the past 6 months; 12. Diagnosed with Diabetes; 13. Is aphakic; or Has entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions. 14. Has undergone refractive error surgery; 15. Has amblyopia or strabismus; 16. Has anisometropia \>2 D between both eyes; 17. Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study; 18. Any grade 3.0 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear; 19. Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)

Design outcomes

Primary

MeasureTime frameDescription
The Total Grade of Conjunctival HyperemiaBaseline to 4-Week Follow-upHyperemia (Redness) was assessed using two different parts of the eye, the Bulbar and the Limbal. Hypemeria was measured using the Efron Scale in 0.5 step units. Grade 0= No Findings, Grade 1= Slight, Grade 2= Mild , Grade 3= Moderate and Grade 4 = severe. Hypermia was assessed in four regions of the eye (Inferior, Nasal, Temporal and Superior). The total grade of Conjunctival Hypermia across all regions and grades is reported. The total grade can range from 0 to 8. Where a higher grade implies worsening conjunctival hypermia
Upper Lid Margin Staining ScoreBaseline to 4-Week Follow-upUpper Lid Margin Staining was assessed using Fluorescein Staining and was measured on the Graded Scale is Grade 0: No Staining is present, Grade 1= 1% to 25% Stains, Grade 2= 26% to 50% Stains, Grade 3= 51% to 75% Stains, Grade 4 76% to 100% Stains. The percentage of eyes with upper lid margin staining for each Grade is reported.
Average Corneal Staining Area GradeBaseline to 4- Week Follow-upCorneal staining Area Grade was assessed in throughout five (5) regions in the eye (Central, Nasal, Temporal, Inferior, Superior). Corneal Staining was Graded using the Efron scale from 0 to 4 in 0.1 unit steps and converted to a percentage of region that was stained. The average percent of region that was stained was calculated and reported.

Countries

Canada

Participant flow

Pre-assignment details

Forty-four (44) subjects were enrolled in this study. Five (5) subjects did not meet the eligibility and were not dispensed a study article. Of the 39 subjects dispensed study lenses all subjects completed the study without any major protocol deviations.

Participants by arm

ArmCount
Multi-focal(Etafilcon A)
All subjects wore the Test Contact Lens, Multi-focal (etafilcon A) as a daily wear modality over a period of four weeks.
39
Total39

Baseline characteristics

CharacteristicMulti-focal(Etafilcon A)
Age, Continuous54.5 Years
STANDARD_DEVIATION 7.05
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
Race/Ethnicity, Customized
Asian
4 Participants
Race/Ethnicity, Customized
Black or African American
2 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 Participants
Race/Ethnicity, Customized
White
33 Participants
Region of Enrollment
Canada
39 Participants
Sex: Female, Male
Female
32 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 39
serious
Total, serious adverse events
0 / 39

Outcome results

Primary

Average Corneal Staining Area Grade

Corneal staining Area Grade was assessed in throughout five (5) regions in the eye (Central, Nasal, Temporal, Inferior, Superior). Corneal Staining was Graded using the Efron scale from 0 to 4 in 0.1 unit steps and converted to a percentage of region that was stained. The average percent of region that was stained was calculated and reported.

Time frame: Baseline to 4- Week Follow-up

Population: The analysis population consists of all subjects that completed all study visits without a major protocol deviation. The analysis was conducted on subject eyes.

ArmMeasureGroupValue (MEAN)Dispersion
BaselineAverage Corneal Staining Area GradeInferior0.039 Average Percentage of StainingStandard Deviation 0.59
BaselineAverage Corneal Staining Area GradeNasal0.08 Average Percentage of StainingStandard Deviation 0.254
BaselineAverage Corneal Staining Area GradeTemporal0.09 Average Percentage of StainingStandard Deviation 0.287
BaselineAverage Corneal Staining Area GradeSuperior0.08 Average Percentage of StainingStandard Deviation 0.32
BaselineAverage Corneal Staining Area GradeCentral0.04 Average Percentage of StainingStandard Deviation 0.025
Multi-focal(Etafilcon A)Average Corneal Staining Area GradeSuperior0.06 Average Percentage of StainingStandard Deviation 0.228
Multi-focal(Etafilcon A)Average Corneal Staining Area GradeCentral0.05 Average Percentage of StainingStandard Deviation 0.297
Multi-focal(Etafilcon A)Average Corneal Staining Area GradeNasal0.06 Average Percentage of StainingStandard Deviation 0.224
Multi-focal(Etafilcon A)Average Corneal Staining Area GradeInferior0.28 Average Percentage of StainingStandard Deviation 0.472
Multi-focal(Etafilcon A)Average Corneal Staining Area GradeTemporal0.03 Average Percentage of StainingStandard Deviation 0.203
Primary

The Total Grade of Conjunctival Hyperemia

Hyperemia (Redness) was assessed using two different parts of the eye, the Bulbar and the Limbal. Hypemeria was measured using the Efron Scale in 0.5 step units. Grade 0= No Findings, Grade 1= Slight, Grade 2= Mild , Grade 3= Moderate and Grade 4 = severe. Hypermia was assessed in four regions of the eye (Inferior, Nasal, Temporal and Superior). The total grade of Conjunctival Hypermia across all regions and grades is reported. The total grade can range from 0 to 8. Where a higher grade implies worsening conjunctival hypermia

Time frame: Baseline to 4-Week Follow-up

Population: The analysis population consists of all subjects that completed all study visits without a major protocol deviation. The analysis is conducted on subject eyes.

ArmMeasureGroupValue (MEAN)Dispersion
BaselineThe Total Grade of Conjunctival HyperemiaBulbar4.25 units on a scaleStandard Deviation 1.261
BaselineThe Total Grade of Conjunctival HyperemiaLimbal3.51 units on a scaleStandard Deviation 1.222
Multi-focal(Etafilcon A)The Total Grade of Conjunctival HyperemiaLimbal3.42 units on a scaleStandard Deviation 1.332
Multi-focal(Etafilcon A)The Total Grade of Conjunctival HyperemiaBulbar3.72 units on a scaleStandard Deviation 1.232
Primary

Upper Lid Margin Staining Score

Upper Lid Margin Staining was assessed using Fluorescein Staining and was measured on the Graded Scale is Grade 0: No Staining is present, Grade 1= 1% to 25% Stains, Grade 2= 26% to 50% Stains, Grade 3= 51% to 75% Stains, Grade 4 76% to 100% Stains. The percentage of eyes with upper lid margin staining for each Grade is reported.

Time frame: Baseline to 4-Week Follow-up

Population: The analysis population consists of all subjects that completed all study visits without a major protocol deviation. The analysis was conducted on subject eyes.

ArmMeasureGroupValue (NUMBER)
BaselineUpper Lid Margin Staining ScoreGrade 0- No Staining46.2 percentage of eyes
BaselineUpper Lid Margin Staining ScoreGrade 3 - 51% to 75% Staining2.6 percentage of eyes
BaselineUpper Lid Margin Staining ScoreGrade 2 - 26% to 50% Staining23.1 percentage of eyes
BaselineUpper Lid Margin Staining ScoreGrade 4 - 76% to 100% Staining0 percentage of eyes
BaselineUpper Lid Margin Staining ScoreGrade 1 - 1% to 25% Staining28.2 percentage of eyes
Multi-focal(Etafilcon A)Upper Lid Margin Staining ScoreGrade 4 - 76% to 100% Staining0.0 percentage of eyes
Multi-focal(Etafilcon A)Upper Lid Margin Staining ScoreGrade 0- No Staining26.9 percentage of eyes
Multi-focal(Etafilcon A)Upper Lid Margin Staining ScoreGrade 2 - 26% to 50% Staining24.4 percentage of eyes
Multi-focal(Etafilcon A)Upper Lid Margin Staining ScoreGrade 3 - 51% to 75% Staining3.9 percentage of eyes
Multi-focal(Etafilcon A)Upper Lid Margin Staining ScoreGrade 1 - 1% to 25% Staining44.9 percentage of eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026